Sign in

CIK 0001738021 · Non-accelerated filer<br>Smaller reporting company

Compass Therapeutics, Inc.

Sign in to watch
Ticker
CMPX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
617-500-8099
Business address
80 GUEST STREET, BOSTON, MA, 02135
Former names
Olivia Ventures, Inc.
  1. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 15,000 shares at $2.83 ($42,450)
  2. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 15,000 shares at $3.05 ($45,750)
  3. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 15,000 shares at $2.64 ($39,600)
  4. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 15,000 shares at $2.58 ($38,700)
  5. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 20,000 shares at $2.80 ($56,000)
  6. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 20,000 shares at $2.34 ($46,800)
  7. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 30,000 shares at $2.29 ($68,700)
  8. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 30,000 shares at $2.83 ($84,900)
  9. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 20,000 shares at $3.03 ($60,600)
  10. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 20,000 shares at $3.04 ($60,800)
  11. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 18,355 shares at $2.72 ($49,926)
  12. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 20,215 shares at $2.47 ($49,931)
  13. 4 Open-market buy Director bought 192,516 shares at an average $2.18 ($420,482)
  14. 4 Open-market buy Director bought 192,516 shares at an average $2.18 ($420,482)
  15. 4 Open-market buy Director bought 125,359 shares at an average $1.57 ($197,252)
  16. 4 Open-market buy Director bought 125,359 shares at an average $1.57 ($197,252)
  17. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 27,836 shares at $1.80 ($50,105)
  18. 4 Derivatives Options or other derivatives
  19. 3 Insider Initial Statement of Ownership
  20. 4 Derivatives Options or other derivatives

Page 5 of 8 · 142 filings